$1.91
0.09[4.95%]
At close: May 31
Cresco Labs
(OTCQX:CRLBF)Cresco Labs Stock (OTC:CRLBF), Analyst Ratings, Price Targets, Predictions
Cresco Labs Inc has a consensus price target of $9.11, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Needham, and Roth MKM on May 16, 2024, May 16, 2024, and March 14, 2024. With an average price target of $1.67 between Wedbush, Needham, and Roth MKM, there's an implied -12.74% downside for Cresco Labs Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Needham
Roth MKM
Cantor Fitzgerald
Cowen & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cresco Labs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 57.07% | Wedbush | Gerald Pascarelli | $2.5 → $3 | Maintains | Outperform | Get Alert |
| 05/16/2024 | Buy Now | — | Needham | Matt McGinley | — | Reiterates | → Hold | Get Alert |
| 03/14/2024 | Buy Now | 4.71% | Roth MKM | Scott Fortune | $1.75 → $2 | Maintains | Neutral | Get Alert |
| 03/20/2023 | Buy Now | 4.71% | Wedbush | Gerald Pascarelli | $4.5 → $2 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 646.07% | Cantor Fitzgerald | Pablo Zuanic | → $14.25 | Maintains | Overweight | Get Alert |
| 12/30/2022 | Buy Now | 646.07% | Cantor Fitzgerald | Pablo Zuanic | $15 → $14.25 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 30.89% | Cowen & Co. | Vivien Azer | $7 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/02/2022 | Buy Now | 135.6% | Wedbush | Gerald Pascarelli | → $4.5 | Initiates | → Outperform | Get Alert |
| 08/18/2022 | Buy Now | 214.14% | Piper Sandler | Michael Lavery | $9 → $6 | Maintains | Overweight | Get Alert |
| 08/18/2022 | Buy Now | 685.34% | Cantor Fitzgerald | Pablo Zuanic | $19 → $15 | Maintains | Overweight | Get Alert |
| 03/24/2022 | Buy Now | 371.2% | Piper Sandler | Michael Lavery | $14 → $9 | Maintains | Overweight | Get Alert |
| 11/15/2021 | Buy Now | 894.76% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
| 11/03/2021 | Buy Now | 528.27% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
| 08/05/2021 | Buy Now | 606.81% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
| 07/07/2021 | Buy Now | 1784.82% | Jefferies | Owen Bennett | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cresco Labs (CRLBF)?
The latest price target for Cresco Labs (OTCQX: CRLBF) was reported by Wedbush on May 16, 2024. The analyst firm set a price target for $3.00 expecting CRLBF to rise to within 12 months (a possible 57.07% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cresco Labs (CRLBF)?
The latest analyst rating for Cresco Labs (OTCQX: CRLBF) was provided by Wedbush, and Cresco Labs maintained their outperform rating.
When was the last upgrade for Cresco Labs (CRLBF)?
There is no last upgrade for Cresco Labs.
When was the last downgrade for Cresco Labs (CRLBF)?
The last downgrade for Cresco Labs Inc happened on December 20, 2022 when Cowen & Co. changed their price target from $7 to $2.5 for Cresco Labs Inc.
When is the next analyst rating going to be posted or updated for Cresco Labs (CRLBF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cresco Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cresco Labs was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Cresco Labs (CRLBF) correct?
While ratings are subjective and will change, the latest Cresco Labs (CRLBF) rating was a maintained with a price target of $2.50 to $3.00. The current price Cresco Labs (CRLBF) is trading at is $1.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.